Fennec Pharmaceuticals/$FENC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Ticker
$FENC
Sector
Primary listing
Employees
35
Headquarters
Website
FENC Metrics
BasicAdvanced
$224m
-
-$0.34
0.93
-
Price and volume
Market cap
$224m
Beta
0.93
52-week high
$9.92
52-week low
$5.65
Average daily volume
207k
Financial strength
Current ratio
6.374
Quick ratio
5.705
Interest coverage (TTM)
-2.93%
Profitability
EBITDA (TTM)
-6.179
Gross margin (TTM)
91.57%
Net profit margin (TTM)
-21.82%
Operating margin (TTM)
-15.11%
Effective tax rate (TTM)
-1.10%
Revenue per employee (TTM)
$1,280,000
Management effectiveness
Return on assets (TTM)
-6.80%
Return on equity (TTM)
-65.82%
Valuation
Price to revenue (TTM)
4.154
Price to book
6.31
Price to tangible book (TTM)
6.31
Price to free cash flow (TTM)
-14.869
Free cash flow yield (TTM)
-6.73%
Free cash flow per share (TTM)
-0.436
Growth
Revenue change (TTM)
-6.09%
Earnings per share change (TTM)
1,604.34%
3-year revenue growth (CAGR)
207.52%
3-year earnings per share growth (CAGR)
-27.72%
10-year earnings per share growth (CAGR)
19.23%
FENC News
AllArticlesVideos
Fennec Pharmaceuticals Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Newsfile Corp·1 month ago
Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Benzinga·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fennec Pharmaceuticals stock?
Fennec Pharmaceuticals (FENC) has a market cap of $224M as of May 01, 2026.
What is the P/E ratio for Fennec Pharmaceuticals stock?
The price to earnings (P/E) ratio for Fennec Pharmaceuticals (FENC) stock is 0 as of May 01, 2026.
Does Fennec Pharmaceuticals stock pay dividends?
No, Fennec Pharmaceuticals (FENC) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next Fennec Pharmaceuticals dividend payment date?
Fennec Pharmaceuticals (FENC) stock does not pay dividends to its shareholders.
What is the beta indicator for Fennec Pharmaceuticals?
Fennec Pharmaceuticals (FENC) has a beta rating of 0.93. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.